KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 72 filers reported holding KALA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $94,000 | +16.0% | 68,051 | +2.2% | 0.00% | – |
| Q4 2021 | $81,000 | -53.7% | 66,591 | -0.0% | 0.00% | – |
| Q3 2021 | $175,000 | -49.1% | 66,621 | +2.8% | 0.00% | – |
| Q2 2021 | $344,000 | -11.1% | 64,824 | +12.9% | 0.00% | -100.0% |
| Q1 2021 | $387,000 | +3.5% | 57,406 | +4.0% | 0.00% | 0.0% |
| Q4 2020 | $374,000 | -4.8% | 55,182 | +5.4% | 0.00% | 0.0% |
| Q3 2020 | $393,000 | -38.1% | 52,372 | -13.3% | 0.00% | 0.0% |
| Q2 2020 | $635,000 | +114.5% | 60,397 | +79.4% | 0.00% | 0.0% |
| Q1 2020 | $296,000 | +164.3% | 33,659 | +11.4% | 0.00% | – |
| Q4 2019 | $112,000 | +2.8% | 30,219 | +5.9% | 0.00% | – |
| Q3 2019 | $109,000 | -35.1% | 28,539 | +8.3% | 0.00% | – |
| Q2 2019 | $168,000 | +4.3% | 26,342 | +35.6% | 0.00% | – |
| Q1 2019 | $161,000 | +114.7% | 19,430 | +27.4% | 0.00% | – |
| Q4 2018 | $75,000 | -49.3% | 15,256 | +41.6% | 0.00% | – |
| Q2 2018 | $148,000 | – | 10,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |